Business Wire

Phase III Study Evaluating the Efficacy and Safety of Lonsurf (trifluridine/tipiracil) in Patients with Metastatic Gastric Cancer Refractory to Standard Therapies (The TAGS Trial) Meets Primary Endpoint

Del

Servier and Taiho Pharmaceutical Co., Ltd. announced today that the pivotal Phase III trial (TAGS) evaluating Lonsurf® (trifluridine/tipiracil) plus best supportive care (BSC) versus Placebo plus BSC in patients with advanced metastatic gastric cancer (mGC) met its primary objective to improve overall survival (OS).

These results will be submitted for presentation at an upcoming international medical conference and will be submitted to a peer-reviewed journal for publication.

About TAGS

The TAGS trial is a global, randomized, double-blind, placebo-controlled trial evaluating Lonsurf® versus Placebo in patients with pretreated metastatic gastric cancer (mGC).

The TAGS trial enrolled 507 patients who had received at least two prior regimens for mGC and who were refractory to, or unable to, tolerate further chemotherapy. Patients were randomized to receive Lonsurf® plus Best Supportive Care or placebo plus BSC in order to investigate the efficacy and safety. The primary endpoint is overall survival (OS) and secondary endpoint measures include progression free survival (PFS), safety and tolerability, as well as quality of life.

For more information on the TAGS trial, please visit https://clinicaltrials.gov/ct2/show/NCT02500043

The ClinicalTrials.gov Identifier is NCT02500043.

About Metastatic Gastric Cancer

Gastric cancer is the fifth most common cancer worldwide and the third most common cause of cancer-related death (after lung and liver cancer), with an estimate of 723,000 deaths annually1. Approximately 50% of patients with gastric cancer have advanced disease at the time of diagnosis2. Standard chemotherapy regimens for advanced gastric cancer include fluoropyrimidines, platinum derivatives, taxanes, ramucirumab or irinotecan. The addition of trastuzumab to chemotherapy is standard of care for patients with HER2-neu-positive advanced gastric cancer. However, after failure of first- and second-line therapies, standard third line treatments are limited.

About Lonsurf

Lonsurf® is an oral anticancer drug, comprising a combination of trifluridine (FTD) and tipiracil (TPI), whose dual mechanism of action is designed to maintain clinical activity. Lonsurf® is registered in Japan, USA, European Union and in many other countries. In the European Union, Lonsurf is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan- based chemotherapies, anti-VEGF agents, and anti-EGFR agents.3

Lonsurf® is recommended by the National Institute for Health and Care Excellence (NICE).4 NCCN2 and ESMO Guidelines5 for the treatment of adult patients with metastatic colorectal cancer.

In June 2015, Servier and Taiho Pharmaceutical entered into an exclusive license agreement for the co-development and commercialization of Lonsurf®.

About Servier

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 148 countries and a turnover of 4.152 billion euros in 2017, Servier employs 21,600 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs.

Becoming a key player in oncology is part of Servier’s long-term strategy. Currently, there are nine molecular entities in clinical development in this area, targeting gastric and lung cancers and other solid tumors, as well as different types of leukemia and lymphomas. This portfolio of innovative cancer treatments is being developed with partners worldwide, and covers different cancer hallmarks and modalities, including cytotoxics, proapoptotics, immune, cellular and targeted therapies, to deliver life-changing medicines to patients.

More information visit: www.servier.com/en/ and www.servier-oncology.com

About Taiho Pharmaceutical Co., Ltd. (Japan)

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd. (https://www.otsuka.com/en/), is an R&D-driven specialty pharma focusing on the three fields of oncology, allergy and immunology, and urology. Its corporate philosophy takes the form of a pledge: “We strive to improve human health and contribute to a society enriched by smiles.” In the field of oncology in particular, Taiho Pharmaceutical is known as a leading company in Japan for developing innovative medicines for the treatment of cancer, a reputation that is rapidly expanding through their extensive global R&D efforts. In areas other than oncology as well, the company creates and markets quality products that effectively treat medical conditions and can help improve people’s quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer consumer healthcare products that support people’s efforts to lead fulfilling and rewarding lives.

For more information about Taiho Pharmaceutical, please visit: https://www.taiho.co.jp/en/

More information is available at: https://servier.com/en/

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr

2. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Gastric cancer. V.1.2018.

3. European Medicines Agency. EPAR Lonsurf. Available from: http://www.ema.europa.eu/ema/

4. NICE TA405. Available at: www.nice.org.uk/guidance/TA405

5. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: Van Cutsem E et al. Ann Oncol. 2016;27:1386-422

Contact information

Servier Media Relations
Sonia MARQUES:
media@servier.com
Tel.: +33(0)155724021 /+33(0)784287613
or
Karine BOUSSEAU:
media@servier.com
Tel.: +33(0)155726037

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Yamaha Motor Outline of Long-term Vision & New Medium-term Management Plan11.12.2018 06:05Pressemelding

Yamaha Motor Co., Ltd. (TOKYO:7272) announced today that it has formulated its long-term vision until 2030, and a New Medium-term Management Plan for the three-year period starting in 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181210005244/en/ (Photo: Business Wire) For its long-term vision, Yamaha Motor has created the slogan “ART for Human Possibilities” and devised a growth strategy heading for 2030. For increasingly diversifying people's values and the environment around societies, the Company will implement its growth strategies while promoting solutions to social issues based on its own historical values. While maintaining the earning power from existing businesses, the new medium-term management plan will allocate resources to strategic growth areas such as new business, and work toward achieving consolidated net sales of 2-trillion yen and a consolidated operating income of 180 billion yen. View source vers

Egon Zehnder Global Board Diversity Tracker Suggests Gender Parity in the Boardroom May Never Be Achieved11.12.2018 06:01Pressemelding

Egon Zehnder, the world's leadership advisory firm, today released the results of its 2018 Global Board Diversity Tracker. The study shows the accelerating growth seen in female directors in Western Europe is now levelling off, and growth elsewhere remains sluggish, suggesting gender parity on boards may never be reached at the current pace. The research, examining data from 1610 public companies with market caps above €7bn in 44 different countries, shows that despite the slow improvement in the number of women on boards, nearly three quarters of all new board positions worldwide still go to men. Jill Ader, Chairwoman of Egon Zehnder, said: “We need diversity, but it’s simply not happening fast enough. New voices and perspectives are essential to unlock the transformational capabilities that businesses tell us they need. Companies - starting from the very top - have to recognize the impact that a critical mass of women on the board and the executive committee makes and take the steps

Rootstock Software Announces New International Channel Partners11.12.2018 06:00Pressemelding

Rootstock Software, a leading cloud Enterprise Resource Planning (ERP) provider for manufacturing, distribution and supply chain organizations on the Salesforce Platform, announced today that the company is continuing to experience significant international growth with the signing of several new partners. These partners will provide Rootstock customers in Europe, the Middle East and Southeast Asia with consulting and implementation services for the company’s Cloud ERP solution. Rootstock Cloud ERP is a flexible, modern and digitally connected ERP solution that provides organizations with real-time management across their entire business, including manufacturing, distribution, supply chain and finance operations. Rootstock’s channel partners will help customers achieve their digital transformation and business goals by leveraging Rootstock to better connect customers, suppliers and employees. When combined with Salesforce, Rootstock Cloud ERP customers enjoy a 360-degree view of all cus

Cred Opens Its Platform to Developers and Businesses10.12.2018 20:21Pressemelding

Cred, the leading provider of crypto-backed lending with over $300 million in credit facilities, today announced the launch of CredX, Cred’s developer platform, enabling any company or developer to turn their products into powerful financial applications for their customers. Crypto exchanges, crypto wallets, miner service providers, even traditional financial institutions have the ability to access Crypto Lending as a Service (CLaaS™) and create a rich set of customer experiences for their customers. “Lending and Earning Crypto are hard businesses to get right, particularly in a bear market,” said Dan Schatt, Co-Founder of Cred and the Universal Protocol Alliance. “A crypto custodian, wallet, merchant or exchange business can now offer their customers compelling credit and treasury management features built directly into their own apps, powered by Cred. Businesses can choose to use their own balance sheets, or leverage Cred’s to provide credit and earning services to generate revenue,

Axonics® Announces Publication of NICE Briefing10.12.2018 16:03Pressemelding

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced today the publication of a Medtech Innovation Briefing by The National Institute for Health and Care Excellence (“NICE”) following a careful review of the innovations offered by the Axonics System. The NICE Medtech Innovation Briefing entitled: “Axonics rechargeable sacral neuromodulation system for overactive bladder and faecal incontinence,” describes published clinical evidence on the Axonics r-SNM System®, confirming efficacy as well as the potential positive economic impact that is possible by the use of the Axonics system in the United Kingdom. The Axonics r-SNM System is the first rechargeable Sacral Neuromodulation system approved for sale in Europe and commercially available to all hospitals and clinics in the U.K. for patients

The Largest Blockchain Conference in Asia to Be Held 30–31 January in Yokohama, Japan10.12.2018 15:00Pressemelding

The Global Blockchain Association (Shimizu Building 6F, 3-19 Hayabusacho, Chiyoda-ku, Tokyo, President: Toshikazu Masuyama) is proud to host the largest blockchain conference in Asia: The Japan Blockchain Conference (JBC) – 2019 Yokohama, to be held on 30 and 31 January at Pacifico Yokohama. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181210005057/en/ The Japan Blockchain Conference (JBC) - 2019 Yokohama (Graphic: Business Wire) The conference will host top companies and organizations from Japan and abroad who represent the future of the rapidly growing blockchain space. This is the place where the leaders of blockchain and crypto can interact, form partnerships, and showcase their leading technologies and developments. We are actively looking for companies to join the best of the blockchain industry and exhibit at our conference. More details can be found here: http://japan-blockchain-c.com/en/ We welcome a wide range of